Recalls and alerts more than 4 years old are automatically archived. While this information can still be accessed in the database, it has not been altered or updated since it was archived. Web pages that are archived on the Web are not subject to the Government of Canada Web Standards. As per the Communications Policy of the Government of Canada, you can request alternate formats by contacting us.

Archived – Another batch of counterfeit lipitor found in the United Kingdom

Starting date:
August 24, 2006
Posting date:
August 24, 2006
Type of communication:
Information Update
Subcategory:
Drugs
Source of recall:
Health Canada
Issue:
Undeclared Substance, Unauthorized products
Audience:
General Public
Identification number:
RA-110001448

Health Canada is informing consumers about a new batch of counterfeit Lipitor (the brand name for atorvastatin) found on the market in the United Kingdom. The counterfeit Lipitor has a lot number of 067404K-3 with an expiration date of "05 2007," sold in a pack size of 28 tablets. Lipitor is used to treat high cholesterol.

This batch of counterfeit Lipitor has a different lot number than in the previous information update posted by Health Canada on August 2, 2006.

The counterfeit Lipitor was originally removed from the market in the U.K. on July 28, 2005, but the product was recently found there again in a pharmacy.

While Health Canada has no indication that any of the counterfeit Lipitor tablets have reached the Canadian market, the product may have been brought into Canada by travellers or been purchased over the Internet.

Health authorities in the U.K. said initial test results indicate that the counterfeit Lipitor does not pose an immediate risk to patients.

As a precaution, Health Canada is issuing this Information Update to alert the public to this matter, as well as to the potential health risks related to counterfeit drugs in general.

Counterfeit drugs may contain the incorrect dose, the wrong ingredients, dangerous additives, or no active ingredients at all, which could result in potentially serious health risks to patients. Even if these drugs do not harm you directly or immediately, your condition may get worse without effective treatment.

In order to minimize the risk of purchasing counterfeit drugs, consumers who choose to purchase their medication via the Internet should not do business with any website or company that:

  • refuses to give a street address, telephone number or way of contacting a pharmacist
  • offers prescription drugs without a prescription
  • offers to issue a prescription based on answers to an online questionnaire
  • claims to have a "miracle cure" for any serious condition
  • sells products that are not approved for sale in Canada

All drugs approved for sale in Canada will either bear an eight-digit Drug Identification Number (DIN), a Natural Product Number (NPN) or a Homeopathic Drug Number (DIN-HM). This authorization indicates that the product has been assessed by Health Canada for safety, efficacy and quality.

Consumers should consult with their pharmacist or their physician if they have experienced any adverse effects from taking Lipitor tablets (or atorvastatin, the active ingredient in Lipitor). Health Canada also encourages health care professionals and consumers to report any suspected adverse reactions associated with the use of a product.

Health Canada advises Canadians to contact the Health Products and Food Branch Inspectorate at 1-800-267-9675 if they believe they have a counterfeit version of this product. If a new batch of counterfeit Lipitor is discovered, the lot number will be added to this information update.

Consumers requiring more details about this Information Update can contact Health Canada's public enquiries line at 613-957-2991, or toll free at 1-866-225-0709.

To report a suspected adverse reaction with this or any other health product, please contact the Canadian Adverse Drug Reaction Monitoring Program (CADRMP) of Health Canada by one of the following methods:

Telephone: 1-866-234-2345
Facsimile: 1-866-678-6789

CADRMP
Marketed Health Products Directorate
Health Protection Building, Tunney's Pasture, AL 0701C
Ottawa, Ontario K1A 0K9
Email: cadrmp@hc-sc.gc.ca

The CADRMPadverse reaction reporting form, including a version that can be completed and submitted online, is located on the MedEffect portal of the Health Canada Web site.

Advisory

Media enquiries

Christopher Williams
Health Canada
613-946-4250

Public enquiries

613-957-2991
1-866-225-0709